PPT-Pharmacotherapy of Hypertension

Victor Nadler Objectives By the end of this class students will be able to Describe the epidemiology of essential hypertension and explain the goals and importance of blood pressure control Describe the contributions of aging obesity and salt sensitivity to the development of hypertension. Weber MD Ernesto L Schiffrin MD William B White MD Samuel Mann MD Lars H Lindholm MD John G Kenerson MD John M Flack MD Barry L Carter Pharm D Barry J Materson MD C Venkata S Ram MD 10 Debbie L Cohen MD 11 JeanClaude Cadet MD 12 Roger R JeanCharles women. Najat. Joubran Fares M.D. St George Hospital . University of . Balamand. Prevalence of high blood pressure by age and race/ethnicity for men and women, US population 18 years of age and older. *Estimate based on sample size not meeting minimum requirements of the National Health and Nutrition Examination Survey III design or relative SEM greater than 30%.. Jay Patel, MD. CR FIRM C. Initial Evaluation. What are the vitals?. EKG. Is this new or old?. What has the rate of increase been?. Is the patient . mentating. well?. Are there signs of acute end-organ damage?. James H. Fischer, . Pharm.D. ., FCCP. May 17, 2011. Pregnancy: Therapeutic Challenges. Determine:. whether physiologic changes impact PKs of drug. what are consequences for drug administration. PK changes tend to be dynamic and unpredictable. Christian Delles. BHF Glasgow Cardiovascular Research . Centre. Institute of Cardiovascular and Medical Sciences. University of Glasgow. Cardiovascular Continuum. Twin studies, pedigree studies. BP variability attributable to all genetic factors: . it . Oscar A. Carretero, M.D.. Hypertension and Vascular Research Division. Department of Medicine. Henry Ford Health System. Detroit, Michigan. 1) What is hypertension or high blood pressure . What’s . all the controversy about . 2015. Kevin M Hayes D.O. FACC. Disclosures. Nothing to disclose. Hypertension guidelines. Thanks for clearing that up for me – NOT Really. Objectives. Brief review of pathophysiology. Putting the Guidelines into Practice. Relationships. . with. commercial . interests. :. Grants/. Research. Support: . Speakers Bureau/. Honoraria. : . Consulting . Fees. : . Data . Safety. and Monitoring: . Jonathan Elliott. Royal Veterinary College. London. Landmarks for feline hypertension research at the RVC. 1992 first BSAVA Clinical Studies Trust Fund grant awarded (Penney Barber appointed - PhD). 1993 Measurement of ionised calcium using electrode methods – is low ionised calcium related to feline hypertension?. Shannon Harris, DNP, FNP. Objectives. Causes of hypertension. Classifications of hypertension. Risk factors. Diagnosis . Complications. Management . Final thoughts. Hypertension. The #1 modifiable risk factor for stroke. Claude K. Lardinois, MD, FACP, MACN, FACE. lardinois@sbcglobal.net. . . Emeritus Professor. University of Nevada School of Medicine, Reno, Nevada. Board Certified Endocrinologist. Medical Director for American Health Care, Rocklin, CA. Identify . differential diagnosis of a case presented with the . symptoms . of lower limb . oedema. .. Differentiate . between different etiologies of . hypertension.. Discuss . briefly between stages of hypertension.. Circulation 2014;129:587-597. Teaching Tool: Hyperfiltration Early Sign of Hypertension and Diabetes. J Am Soc Nephrol 2017;28:1023-1039. Hyperfiltration Early in . Diabetic Nephropathy. Circulation 2016;134:752-772. Hypertension . doubles the risk of cardiovascular diseases, including coronary heart disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, renal failure, and peripheral arterial disease.